AEROVATE THERAPEUTICS INC's ticker is AVTE and the CUSIP is 008064107. A total of 47 filers reported holding AEROVATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,672,609 | -20.9% | 2,039,249 | 0.0% | 4.29% | -1.5% |
| Q2 2023 | $34,973,120 | -15.0% | 2,039,249 | 0.0% | 4.35% | -21.9% |
| Q1 2023 | $41,131,652 | -30.4% | 2,039,249 | +1.1% | 5.57% | -21.8% |
| Q4 2022 | $59,113,365 | +53.2% | 2,017,521 | -13.3% | 7.12% | +67.2% |
| Q3 2022 | $38,597,000 | -6.4% | 2,327,909 | -11.8% | 4.26% | -38.2% |
| Q2 2022 | $41,237,000 | -27.5% | 2,638,297 | -15.0% | 6.89% | -4.2% |
| Q1 2022 | $56,894,000 | +55.5% | 3,103,879 | 0.0% | 7.19% | +114.0% |
| Q4 2021 | $36,595,000 | – | 3,103,879 | – | 3.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| OUP Management Co., LLC | 603,762 | $10,010,000 | 15.59% |
| TCG Crossover Management, LLC | 959,572 | $15,910,000 | 4.77% |
| Atlas Venture Life Science Advisors, LLC | 2,327,909 | $38,597,000 | 4.26% |
| Lynx1 Capital Management LP | 276,447 | $4,583,000 | 4.13% |
| Sofinnova Investments, Inc. | 3,758,686 | $62,319,000 | 3.63% |
| RA Capital Management | 8,263,982 | $137,017,000 | 2.92% |
| Cormorant Asset Management, LP | 2,330,691 | $38,643,000 | 2.70% |
| VR Adviser, LLC | 833,927 | $13,827,000 | 2.13% |
| Ghost Tree Capital, LLC | 150,000 | $2,487,000 | 0.70% |
| Ikarian Capital, LLC | 200,000 | $3,316,000 | 0.66% |